Eric J Feldman
Overview
Explore the profile of Eric J Feldman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
2026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, et al.
Blood
. 2025 Feb;
PMID: 39919267
Venetoclax combined with intensive chemotherapy shows promise for untreated acute myeloid leukemia (AML), but its integration with the '7+3' regimen remains underexplored. In a phase 1b study (NCT05342584), we assessed...
2.
Cooper D, Verceles J, Kheradmand T, Paroder M, Lombardo A, Goldfinger M, et al.
Br J Haematol
. 2025 Feb;
206(3):1004-1006.
PMID: 39915967
No abstract available.
3.
Kamel J, Yan J, Rockwell B, Goldfinger M, Feldman E, Konopleva M, et al.
Leuk Lymphoma
. 2024 Oct;
66(2):329-332.
PMID: 39432864
No abstract available.
4.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica R, et al.
Blood
. 2024 Sep;
144(22):2360-2363.
PMID: 39316768
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for...
5.
Hammami M, Verceles J, Goldfinger M, Shah N, Sica R, Mantzaris I, et al.
Transplant Cell Ther
. 2024 Feb;
30(5):544.e1-544.e8.
PMID: 38417677
Recent advances in graft-versus-host disease (GVHD) prophylaxis including post-transplant cyclophosphamide (PTCy) and abatacept have significantly improved outcomes following HLA-mismatched allogenic hematopoietic stem cell transplantation (allo-HSCT) and have tremendous potential for...
6.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro L, Mantzaris I, Shastri A, et al.
Clin Cancer Res
. 2023 Jun;
29(15):2774-2780.
PMID: 37341641
Purpose: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for elderly patients with acute myeloid leukemia (AML) and is being evaluated...
7.
DeAngelo D, Jonas B, Liesveld J, Bixby D, Advani A, Marlton P, et al.
Blood
. 2021 Sep;
139(8):1135-1146.
PMID: 34543383
Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A...
8.
Li F, Sutherland M, Yu C, Walter R, Westendorf L, Valliere-Douglass J, et al.
Mol Cancer Ther
. 2017 Nov;
17(2):554-564.
PMID: 29142066
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the...
9.
Garfin P, Feldman E
Curr Hematol Malig Rep
. 2016 Oct;
11(6):545-552.
PMID: 27734262
While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid...
10.
Feldman E
Clin Lymphoma Myeloma Leuk
. 2015 Aug;
15 Suppl:S91-3.
PMID: 26297287
Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resistance to standard chemotherapy regimens. Emerging...